Damien Dauphinee, DPM
Foot & Ankle Surgery · Denton, TXNPI 1629075288
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Merck at 44.3% of the total. Reporting peaked in 2019 at $40,038 and has fallen 89.7% since, to $4,111 in 2025. Among foot & ankle surgery clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 365 payments — averaging $191.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$31K
- Smith+Nephew$20K
- Stryker$8K
- Biotissue Holdings Inc.$5K
- Tulavi Therapeutics, Inc.$2K
- Imbed Biosciences Inc.$2K
- plus $2K from 17 others
Across 19 payments — averaging $613.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Axogen$11K
- Tyber Medical, LLC$550
What the payments were for
- Consulting fees$2,3503%
- Speaking & faculty fees$40,40358%
- Travel & lodging$14,26120%
- Food & beverage$12,84518%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 37 | $30,970 |
| Smith+Nephew | 94 | $20,011 |
| Stryker(2 entities) | 94 | $7,689 |
| Biotissue Holdings Inc. | 74 | $5,433 |
| Tulavi Therapeutics, Inc. | 2 | $2,365 |
| Imbed Biosciences Inc. | 23 | $1,727 |
| Axogen | 7 | $279 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $254 |
| Bioventus LLC | 4 | $131 |
| Amgen | 5 | $130 |
| Orthofix Medical, Inc. | 2 | $127 |
| Heron Therapeutics, Inc. | 1 | $108 |
| Cepheid | 1 | $100 |
| Comsort, Inc | 1 | $100 |
| Integra Lifesciences Corporation | 1 | $74 |
| Organogenesis Inc. | 3 | $70 |
| Tactile Systems Technology Inc | 5 | $65 |
| Nevro Corp. | 3 | $62 |
| Johnson & Johnson | 2 | $57 |
| Normatec Industries, LP | 2 | $54 |
| IBSA Pharma Inc. | 1 | $23 |
| Kerecis Limited | 1 | $16 |
| Osiris Therapeutics Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SIVEXTRO$30,723
- COLLAGENASE SANTYL$9,919
- REGRANEX$8,055
- Santyl$3,336
- Oasis$2,878
- NEOX$2,833
- CLARIX$2,833
- ALLAY NERVE CAP - SMALL NERVE SET$2,365
- PRIME SERIES$1,630
- INBONE$1,550
- AUGMENT INJECTABLE$1,065
- INFINITY$604
- PROstep$478
- Actishield$231
- INFINITY ADAPTIS$175
- CITREFIX$157
- Physio-Stim$123
- AVANCE NERVE GRAFT$120
- Zynrelef$108
- DART-FIRE$101
How this compares
$69,858 in reported general payments places this provider in the 90th percentile of 684 foot & ankle surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JubliaEfinaconazole | 14 | $19,423 |
| Gabapentin | 45 | $697 |
| Cefdinir | 13 | $156 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $140 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Denton
- Stuart MichnickDenton$107K
- William McGarveyKaty$3.5M
- Eugene CurryDallas$3.1M
- Graham HamiltonEdinburg$2.1M
- Mark DaltonAustin$1.9M
- Kevin VarnerHouston$1.1M
- Paul KimDallas$928K
- Sherman NaglerHouston$602K
- John EarlyDallas$553K
- Michael DowneySouthlake$475K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.